258 related articles for article (PubMed ID: 25762519)
1. Improved pruritus correlates with lower levels of IL-31 in CTCL patients under different therapeutic modalities.
Cedeno-Laurent F; Singer EM; Wysocka M; Benoit BM; Vittorio CC; Kim EJ; Yosipovitch G; Rook AH
Clin Immunol; 2015 May; 158(1):1-7. PubMed ID: 25762519
[TBL] [Abstract][Full Text] [Related]
2. Histone Deacetylase Inhibitors for Cutaneous T-Cell Lymphoma.
Duvic M
Dermatol Clin; 2015 Oct; 33(4):757-64. PubMed ID: 26433847
[TBL] [Abstract][Full Text] [Related]
3. Relief of intractable pruritus with romidepsin in patients with cutaneous T-cell lymphoma: A series of four cases.
Poligone B; Rubio-Gonzalez B; Querfeld C
Dermatol Ther; 2019 Mar; 32(2):e12804. PubMed ID: 30549384
[TBL] [Abstract][Full Text] [Related]
4. Activity of deacetylase inhibitor panobinostat (LBH589) in cutaneous T-cell lymphoma models: Defining molecular mechanisms of resistance.
Shao W; Growney JD; Feng Y; O'Connor G; Pu M; Zhu W; Yao YM; Kwon P; Fawell S; Atadja P
Int J Cancer; 2010 Nov; 127(9):2199-208. PubMed ID: 20127862
[TBL] [Abstract][Full Text] [Related]
5. Kinome profiling analysis identified Src pathway as a novel therapeutic target in combination with histone deacetylase inhibitors for cutaneous T-cell lymphoma.
Jimura N; Fujii K; Qiao Z; Tsuchiya R; Yoshimatsu Y; Kondo T; Kanekura T
J Dermatol Sci; 2021 Mar; 101(3):194-201. PubMed ID: 33531202
[TBL] [Abstract][Full Text] [Related]
6. Histone deacetylase inhibitors inhibit metastasis by restoring a tumor suppressive microRNA-150 in advanced cutaneous T-cell lymphoma.
Abe F; Kitadate A; Ikeda S; Yamashita J; Nakanishi H; Takahashi N; Asaka C; Teshima K; Miyagaki T; Sugaya M; Tagawa H
Oncotarget; 2017 Jan; 8(5):7572-7585. PubMed ID: 27935859
[TBL] [Abstract][Full Text] [Related]
7. The histone deacetylase inhibitors vorinostat and romidepsin downmodulate IL-10 expression in cutaneous T-cell lymphoma cells.
Tiffon C; Adams J; van der Fits L; Wen S; Townsend P; Ganesan A; Hodges E; Vermeer M; Packham G
Br J Pharmacol; 2011 Apr; 162(7):1590-602. PubMed ID: 21198545
[TBL] [Abstract][Full Text] [Related]
8. IL-22, but not IL-17, dominant environment in cutaneous T-cell lymphoma.
Miyagaki T; Sugaya M; Suga H; Kamata M; Ohmatsu H; Fujita H; Asano Y; Tada Y; Kadono T; Sato S
Clin Cancer Res; 2011 Dec; 17(24):7529-38. PubMed ID: 22048239
[TBL] [Abstract][Full Text] [Related]
9. The polymorphisms of IL-6/STAT3 signaling pathway may contribute to cutaneous T-cell lymphomas susceptibility.
Olszewska B; Gleń J; Zabłotna M; Nowicki RJ; Sokołowska-Wojdyło M
Arch Dermatol Res; 2021 Jan; 313(1):25-31. PubMed ID: 32270320
[TBL] [Abstract][Full Text] [Related]
10. Deficient cutaneous antibacterial competence in cutaneous T-cell lymphomas: role of Th2-mediated biased Th17 function.
Wolk K; Mitsui H; Witte K; Gellrich S; Gulati N; Humme D; Witte E; Gonsior M; Beyer M; Kadin ME; Volk HD; Krueger JG; Sterry W; Sabat R
Clin Cancer Res; 2014 Nov; 20(21):5507-16. PubMed ID: 25212608
[TBL] [Abstract][Full Text] [Related]
11. Synergy of BCL2 and histone deacetylase inhibition against leukemic cells from cutaneous T-cell lymphoma patients.
Cyrenne BM; Lewis JM; Weed JG; Carlson KR; Mirza FN; Foss FM; Girardi M
Blood; 2017 Nov; 130(19):2073-2083. PubMed ID: 28972015
[TBL] [Abstract][Full Text] [Related]
12. Malignancy-associated pruritus.
Rowe B; Yosipovitch G
Eur J Pain; 2016 Jan; 20(1):19-23. PubMed ID: 26416212
[TBL] [Abstract][Full Text] [Related]
13. Analysis of STAT4 expression in cutaneous T-cell lymphoma (CTCL) patients and patient-derived cell lines.
Litvinov IV; Cordeiro B; Fredholm S; Ødum N; Zargham H; Huang Y; Zhou Y; Pehr K; Kupper TS; Woetmann A; Sasseville D
Cell Cycle; 2014; 13(18):2975-82. PubMed ID: 25486484
[TBL] [Abstract][Full Text] [Related]
14. Cutaneous T-cell Lymphoma and Pruritus: The Expression of IL-31 and its Receptors in the Skin.
Nattkemper LA; Martinez-Escala ME; Gelman AB; Singer EM; Rook AH; Guitart J; Yosipovitch G
Acta Derm Venereol; 2016 Nov; 96(7):894-898. PubMed ID: 27001482
[TBL] [Abstract][Full Text] [Related]
15. Association of nerve growth factor, chemokine (C-C motif) ligands and immunoglobulin E with pruritus in cutaneous T-cell lymphoma.
Suga H; Sugaya M; Miyagaki T; Ohmatsu H; Fujita H; Kagami S; Asano Y; Tada Y; Kadono T; Sato S
Acta Derm Venereol; 2013 Mar; 93(2):144-9. PubMed ID: 22948508
[TBL] [Abstract][Full Text] [Related]
16. IL-31 is produced by the malignant T-cell population in cutaneous T-Cell lymphoma and correlates with CTCL pruritus.
Singer EM; Shin DB; Nattkemper LA; Benoit BM; Klein RS; Didigu CA; Loren AW; Dentchev T; Wysocka M; Yosipovitch G; Rook AH
J Invest Dermatol; 2013 Dec; 133(12):2783-2785. PubMed ID: 23698099
[No Abstract] [Full Text] [Related]
17. Romidepsin: a histone deacetylase inhibitor for refractory cutaneous T-cell lymphoma.
Kim M; Thompson LA; Wenger SD; O'Bryant CL
Ann Pharmacother; 2012 Oct; 46(10):1340-8. PubMed ID: 22968522
[TBL] [Abstract][Full Text] [Related]
18. Expression of interleukin-18 and caspase-1 in cutaneous T-cell lymphoma.
Yamanaka K; Clark R; Dowgiert R; Hurwitz D; Shibata M; Rich BE; Hirahara K; Jones DA; Eapen S; Mizutani H; Kupper TS
Clin Cancer Res; 2006 Jan; 12(2):376-82. PubMed ID: 16428475
[TBL] [Abstract][Full Text] [Related]
19. Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL).
Duvic M; Talpur R; Ni X; Zhang C; Hazarika P; Kelly C; Chiao JH; Reilly JF; Ricker JL; Richon VM; Frankel SR
Blood; 2007 Jan; 109(1):31-9. PubMed ID: 16960145
[TBL] [Abstract][Full Text] [Related]
20. Pruritus in cutaneous T-cell lymphoma: a review.
Ahern K; Gilmore ES; Poligone B
J Am Acad Dermatol; 2012 Oct; 67(4):760-8. PubMed ID: 22285672
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
